Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan vs Chemotherapy in Endometrial Cancer
NCT06132958Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in endometrial cancer (EC), sponsored by Merck & Co.. Started Dec 2023; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06132958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132958.